Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention
Aggregate Results From 6 Randomized, Controlled Trials

Derek P. Chew, MBBS; Deepak L. Bhatt, MD; A. Michael Lincoff, MD; David J. Moliterno, MD; Sorin J. Brener, MD; Katherine E. Wolski, MS; Eric J. Topol, MD

Background—Unfractionated heparin has been the primary anticoagulant therapy for percutaneous coronary intervention for >20 years. Despite the availability of rapid “point of care” testing, little clinical data defining the optimal level of anticoagulation are available. Furthermore, recent reports have advocated the use of low-dose heparin regimens in the absence of large-scale, well-conducted studies to support this practice.

Methods and Results—We pooled the data from 6 randomized, controlled trials of novel adjunctive antithrombotic regimens for percutaneous coronary interventions in which unfractionated heparin constituted the control arm. Patients were divided into 25-s intervals of activated clotting times (ACTs), from <275 s to >476 s. In a total of 5216 patients, the incidence of death, myocardial infarction, or any revascularization and major or minor bleeding at 7 days were calculated for each group and compared. An ACT in the range of 350 to 375 s provided the lowest composite ischemic event rate of 6.6%, or a 34% relative risk reduction in 7-day ischemic events compared with rates observed between 171 and 295 s by quartile analysis (P = 0.001).

Conclusions—Contrary to recent reports, the optimal suppression of ischemic events with unfractionated heparin therapy in patients undergoing percutaneous coronary intervention demands treatment to ACT levels that are substantially higher than currently appreciated. These data define a goal for heparin dosing within coronary interventions and establish a benchmark of optimal unfractionated heparin therapy against which future trials of novel antithrombotic regimens in percutaneous interventions can be compared. (Circulation. 2001;103:961-966.)

Key Words: heparin ■ clinical trials ■ pharmacology ■ coagulation

Since the development of percutaneous coronary intervention (PCI), intravenous unfractionated heparin has remained the primary antithrombotic therapy for the prevention of periprocedural ischemic complications.1 Adequate dosing with unfractionated heparin effectively suppresses the thrombin generation associated with balloon-induced vascular injury.2 Despite the continued evolution of antithrombotic therapies, unfractionated heparin remains an attractive option given its relatively low cost, the availability of a rapid “point of care” test for dose individualization (the activated clotting time [ACT]), and a known antagonist that allows the prompt reversal of antithrombin activity. Therefore, considering the wealth of experience associated with the clinical use of this agent, an optimal level of anticoagulation should be attainable in most patients undergoing PCI. However, defining this optimal level of ACT has been hampered by the lack of large-scale, randomized data. Current recommendations of ACT levels of 300 to 350 s are empiric3 and based on relatively small studies.4–6 Furthermore, in clinical practice, periprocedural heparin dosing varies markedly, with a recent emerging trend toward the use of lower heparin doses, despite the support of only a few small observational series.7,8 Therefore, we performed an analysis combining individual patient data from 6 randomized, controlled trials to determine the optimum range of ACT for the suppression of periprocedural ischemic events after PCI.

Methods

Trial Selection, Heparin Treatments, and ACT Measures

Trial selection was confined to studies of novel pharmacotherapies in the setting of PCI using aspirin and unfractionated heparin as the comparator arm. Routine ACT monitoring before device activation, the maximum ACT during the procedure, and 7-day follow-up documenting death, myocardial infarction (MI), urgent revascularization, and major or minor bleeding were also required for inclusion in our combined data set. Therefore, 6 randomized, controlled trials of patients undergoing PCI were available. These trials are summarized in Table 1.9–14 ACT values were drawn from the placebo arms of these studies, and a comparative analysis was also performed in the abciximab-treated patients from the Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) trial, Evaluation in...
TABLE 1. Summary of Trials

<table>
<thead>
<tr>
<th>Intervention</th>
<th>EPIC&lt;sup&gt;9&lt;/sup&gt; (n=2099)</th>
<th>EPILOG&lt;sup&gt;10&lt;/sup&gt; (n=2792)</th>
<th>EPISTENT&lt;sup&gt;13&lt;/sup&gt; (n=2399)</th>
<th>IMPACT II&lt;sup&gt;11&lt;/sup&gt; (n=4100)</th>
<th>RAPPORT&lt;sup&gt;13&lt;/sup&gt; (n=438)</th>
<th>Hirudin Angioplasty Study&lt;sup&gt;12&lt;/sup&gt; (n=4098)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo arm</td>
<td>Heparin bolus (10 000–12 000 U)</td>
<td>Heparin bolus (100 U/kg)</td>
<td>Heparin bolus (100 U/kg)</td>
<td>Heparin bolus (100 U/kg)</td>
<td>Heparin bolus (100 U/kg)</td>
<td>Heparin bolus (175 U/kg)</td>
</tr>
<tr>
<td>Maximum heparin dose</td>
<td>20 000 U</td>
<td>10 000 U</td>
<td>10 000 U</td>
<td>10 000 U</td>
<td>10 000 U</td>
<td>295 U/kg</td>
</tr>
<tr>
<td>Targeted ACT, s</td>
<td>300–350</td>
<td>≥300</td>
<td>≥300</td>
<td>≥300</td>
<td>≥300</td>
<td>350</td>
</tr>
<tr>
<td>Minimum ACT at device implementation, s</td>
<td>274±108</td>
<td>320±74</td>
<td>312±69</td>
<td>233±85</td>
<td>220±110</td>
<td>303±164</td>
</tr>
<tr>
<td>Maximum ACT, s</td>
<td>346±129</td>
<td>372±134</td>
<td>377±130</td>
<td>354±147</td>
<td>386±270</td>
<td>442±179</td>
</tr>
<tr>
<td>Population</td>
<td>High-risk PTCA</td>
<td>All patients</td>
<td>All patients</td>
<td>High-risk PTCA</td>
<td>Acute MI</td>
<td>Unstable angina</td>
</tr>
</tbody>
</table>

Values are mean±SD or n (%).

EPIC indicates Evaluation of c7E3 for the Prevention of Ischemic Complications; EPILOG, Evaluation in PTCA to Improve Long-Term Outcome with abciximab Glycoprotein IIb/IIIa blockade; EPISTENT, Evaluation of IIb/IIIa Platelet Inhibitor for Stenting; IMPACT II, Integrihin to Minimize Platelet Aggregation and Coronary Thrombosis II; and RAPPORT, Reopro and Primary PTCA Organization and Randomized Trial.

PTCA to Improve Long-term Outcome with abciximab Glycoprotein IIb/IIIa blockade (EPILOG) trial, Evaluation of IIb/IIIa Platelet Inhibitor for Stenting (EPISTENT) trial, and ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT). Each protocol targeted an ACT level >300 s in the control arms. The device used to assay the ACT was specified in all but 904 patients. The HemoChron assay (International Technidyne Corporation) and the HemoTec assay (HemoTec Inc) were used in 95% and 5% of patients, respectively, in whom the device used was recorded.

Among the trials, mean minimum ACT levels at device activation were similar, whereas the mean maximum ACTs varied more substantially. The minimum ACT at device activation was analyzed with regard to ischemic events at 7 days because this value was considered to reflect the degree of antithrombotic therapy at vascular injury most closely. Conversely, the maximum ACT at any time during the procedure was assessed relative to bleeding events, because this value reflects the greatest risk of bleeding to which the patient was exposed.

Statistical Methods

The minimum ACTs at or around the time of device activation were collected and divided into the following groups: <275 s, 275 to 300 s, 301 to 325 s, 326 to 350 s, 351 to 375 s, 376 to 400 s, 401 to 425 s, 426 to 475 s, and >476 s. The incidence of peri-procedural ischemic events within each group was calculated. The maximum ACT during the procedure was also recorded and similarly divided, and the incidence of bleeding events was calculated for each range. Subgroup analyses were also performed for patients with diabetes and acute coronary syndromes and those receiving stents. The end point definitions for death, MI, and urgent revascularization were as defined in the individual protocols, and they were similar among the trials. The definition of bleeding end points for the Hirulog Angioplasty Study<sup>12</sup> varied substantially from the other 5 studies and, therefore, it was omitted from the bleeding analysis.

Baseline characteristics are expressed as percentages for discrete variables or as mean±SD for continuous variables. Event rates for each ACT interval were calculated as the percentage of patients experiencing an event within the specific ACT interval. Examination of event rates as quartiles of minimum ACT at device activation was also undertaken to minimize the effect of small sample sizes across some ranges of ACT. The χ² statistic was used to compare the lowest and highest event rates in the arbitrarily determined ACT ranges and to compare event rates among the quartiles. P<0.05 was considered significant. The Lowess smoothing function was used to generate graphic representations of the relationships between increasing ACT and outcomes.

Results

Population Characteristics

In total, 6146 patients received unfractionated heparin alone and 5216 patients (85%) had ACT data available at or around the time of device activation. Maximum ACT results were available for 5444 patients (89%); however, with the Hirulog Angioplasty Study excluded, 3485 patients (64%) were used in the bleeding analysis. The demographic and procedural characteristics of all patients are presented in Table 2. Importantly, patients with acute coronary syndromes represented a substantial proportion of the population studied.

TABLE 2. Demographics and Procedural Characteristics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All Studies Pooled</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total No. of patients</td>
<td>6146</td>
</tr>
<tr>
<td>Age, y</td>
<td>60.5±10.9</td>
</tr>
<tr>
<td>Current smoker</td>
<td>1802 (29.5)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>1369 (22.3)</td>
</tr>
<tr>
<td>Acute coronary syndrome</td>
<td>3699 (60.2)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3399 (55.4)</td>
</tr>
<tr>
<td>History of CHF</td>
<td>365 (6.0)</td>
</tr>
<tr>
<td>Prior CABG</td>
<td>746 (12.1)</td>
</tr>
<tr>
<td>Prior PCI</td>
<td>1489 (24.3)</td>
</tr>
<tr>
<td>Prior MI</td>
<td>2832 (46.1)</td>
</tr>
<tr>
<td>Procedure &gt;60 min</td>
<td>1549 (26.6)</td>
</tr>
<tr>
<td>Initial heparin dose, U</td>
<td>10 439±3985</td>
</tr>
<tr>
<td>Total heparin dose, U</td>
<td>14 203±5895</td>
</tr>
<tr>
<td>Mean ACT at device activation, s</td>
<td>283±132</td>
</tr>
<tr>
<td>Maximum ACT, s</td>
<td>398±191</td>
</tr>
<tr>
<td>Any stent</td>
<td>936 (15.3)</td>
</tr>
<tr>
<td>1 Vessel disease</td>
<td>4020 (65.4)</td>
</tr>
<tr>
<td>2 Vessel disease</td>
<td>1360 (22.1)</td>
</tr>
<tr>
<td>3 Vessel disease</td>
<td>606 (9.9)</td>
</tr>
</tbody>
</table>

Values are mean±SD or n (%).
In addition, 15% of all patients received $1$ stent, and a procedural duration of $1$ hour was observed in 27% of cases.

### ACT at Device Activation and Ischemic Events

The relationship between increasing ACT and ischemic events (n = 5216) followed a U-shaped curve. A progressive reduction in the risk of death, MI, and urgent revascularization was observed with increasing ACT levels, as evidenced by a reduction in the composite ischemic end point from 11.1% at an ACT of 275 to 300 s to a nadir of 6.6% with an ACT of 350 to 375 s ($\chi^2$ statistic between highest event rate and lowest event rate, $P=0.026$). Beyond this level of ACT, the risk of ischemic events rises, increasing to 9.3% at ACT levels.

### Subgroups

Analysis of diabetics included 1135 patients with available ACT data (83%). Correlations between the minimum ACT at device activation and ischemic events at 7 days demonstrated a similar U-shaped relationship. In comparison with the nondiabetic population and the overall population, a more pronounced reduction in ischemic events was evident between ACT levels of 350 to 375 s compared with those of 275 to 300 s in diabetic patients (Figure 3). Assessment of outcomes in the diabetic population when stratified by the same ACT ranges defined by the overall population demonstrated a 38% reduction in 7-day composite ischemic events in these ACT ranges (ACT of 171 to 295 s, 12.5%; ACT $\geq 350$ s, 7.7%; $P=0.062$).

### Concurrent Abciximab

With concurrent abciximab administration (n = 4362), analysis of the 4 abciximab trials demonstrates lower ischemic event rates across the entire range of ACT values. However, in the 3458 patients with available minimum ACT data, the U-shaped relationship is no longer evident, with a plateau in the ischemic event rate of $\leq 4.5\%$ at 7 days across a broad range of values (275 to 375 s; Figure 4A). Data for maximum ACT were available for a total of 3876 patients. The correlation between the maximum ACT and major or minor bleeding events demonstrated a slightly increased rate of bleeding with abciximab compared with heparin alone across the ranges of 275 to 375 s, with a substantial increase associated with ACTs beyond this level (Figure 4B).

### Discussion

This analysis of individual patient data derived from the placebo arms of 6 randomized glycoprotein IIb/IIIa trials represents the largest study correlating the level of unfrac-
tionated heparin therapy and early postprocedural outcome. From these large-scale PCI trials, an optimal range of ACT for unfractionated heparin therapy of between 350 and 375 s is evident; this range is substantially higher than previously appreciated. Considering that more than two thirds of the patients within this analysis presented with an episode of coronary instability, this degree of anticoagulation seems to confer a low ischemic event rate of 6.6%, as defined by the composite end point of death, MI, or urgent revascularization at 7 days. This analysis runs contrary to the widely held clinical impression suggesting that lower dosing with unfractionated heparin is associated with equivalent clinical outcomes.

Recent reports have advocated the use of very-low-dose unfractionated heparin (2500 to 5000 U) among patients undergoing PCI. In a single-center observational study of 1375 patients receiving 5000 U of heparin before PCI, Koch and coworkers7 observed a relatively low rate of death, MI, or repeat revascularization of 5.4% at 48 hours. However, in addition to the shorter duration of follow-up, patients with acute coronary syndromes and those patients undergoing stenting were excluded from the analysis, and diabetics constituted only 10% of the study population. Similarly, Kaluski et al8 reported a 3.3% event rate for death, MI, and urgent revascularization with 2500 U of heparin before PCTA, but postprocedural creatine kinase was not routinely assayed, which likely underestimated the incidence of periprocedural MI.8 Vainer and colleagues15 performed a small trial of 404 patients randomized to either 5000 or 20 000 U of heparin before PCI. In the low-dose heparin group, only 22% of patients attained an ACT $>275$ s. This group had a composite event rate for death, MI, repeat revascularization, or acute occlusion of 13.2%; the rate for the high-dose group was 8% ($P$=NS). This lack of statistical significance has been interpreted as support for low-dose heparin regimens,8 although an inadequate sample size is a more likely explanation.

This current analysis refutes the notion that low-dose heparin therapy provides an efficacy similar to that of higher doses in PCI. Thus, whereas a previous trial attempting to demonstrate superior safety and efficacy with weight-individualized heparin dosing over a fixed-dosing regimen has been inconclusive,16 these data identify a therapeutic goal for unfractionated heparin therapy in individuals undergoing PCI. Furthermore, by increasing the therapeutic goal to $>350$
s, we observed a 34% relative risk reduction in ischemic events at 7 days. However, an increase in bleeding events is evident at this optimal range of ACT.

Previous authors have also attempted to define a threshold beyond which additional heparin provided no further incremental benefit. In the setting of a 186-patient, single-center, case-control study drawn from a registry of 1290 patients, Narins and coworkers were unable to determine a “safe threshold” for the ACT, observing an inverse relationship between ACT and ischemic events that remained linear through the observed ACT values. Likewise, Bittl et al reported a similar relationship in the 2039 heparin-treated patients from the randomized trial of bivalirudin in PCI. In contrast, the present analysis demonstrates a U-shaped curve for ischemic risk, with ACT levels greater than \( \approx 400 \) s associated with a greater rate of ischemic events, as observed in patients with acute MI undergoing thrombolytic therapy. The excess thrombotic risk observed at higher ACTs likely represents the clinical confirmation of the platelet activation observed with high doses of unfractionated heparin within in vitro models and ex vivo studies. Interestingly, from this analysis, concurrent glycoprotein IIb/IIIa therapy seems to ameliorate the ischemic risk associated with high ACT levels, reinforcing the thrombotic pathophysiology of these events; this, again, is consistent with heparin-induced platelet activation. A similar analysis of bivalirudin therapy observed no increase in ischemic events at high levels of anticoagulation, possibly reflecting an absence of platelet activation observed with direct thrombin inhibitors.

The impact of concurrent abciximab on the ACT has been previously defined, and this synergy has implications for the optimal dosing of heparin in abciximab-treated patients. This meta-analysis confirms the dictum of targeting lower ACTs when heparin and abciximab are combined, demonstrating a true inverse relationship between increasing ACT and ischemic events. Overall ischemic event rates are, as expected, reduced in comparison with heparin-only–treated patients for all levels of ACT, with a plateau across a broad range (250 to 350 s). Because the ability to inhibit thrombin generation and prolong the ACT varies among glycoprotein IIb/IIIa inhibitors, a similar relationship between heparin, ACT levels, and epifibatide or tirofiban cannot necessarily be expected; this requires formal definition.

The association between diabetes and adverse outcomes after PCI is well established. Abnormalities in baseline platelet function and coagulation may partially account for the increased risk. Complementing the previous observation that diabetics undergoing PCI benefit from higher heparin doses despite concurrent abciximab use, this analysis demonstrates a more prominent reduction in adverse ischemic events associated with achieving ACT levels of \( \approx 350 \) s in the absence of concurrent abciximab therapy. By quartile analysis, achieving this higher ACT level provided a 38% relative risk reduction in 7-day composite ischemic events, although this reduction did not reach statistical significance due to the smaller sample size.

Beyond daily clinical practice, this meta-analysis has implications for the design of future trials investigating pharmacotherapies in PCI. Many recent studies have used heparin doses designed to achieve ACT levels that are substantially lower than those advocated by this analysis. Therefore, whether the incremental benefit over standard unfractionated heparin therapy defined by these studies would hold true with optimal heparin dosing remains uncertain. Although not the case for adjunctive abciximab therapy in the nondiabetic population, more aggressive heparin dosing may provide a greater suppression of ischemic events within the placebo arm, reducing the relative and absolute benefit of the investigational therapy. In future PCI trials in which aspirin, unfractionated heparin, and thienopyridines are used as the placebo-comparator arm, targeting heparin therapy to ACT levels in the range of 350 to 375 s would be required to define the true relative benefit of any novel therapy.

**Limitations**

ACT data were incomplete and, therefore, the potential for unanticipated selection biases remains. However, with such a large population, omission of data are likely to be randomly distributed across the observed ACT values. Consistent with this, analysis of demographic and procedural variables among patients without ACT data seemed similar to those in patients in whom data were available. Similarly, despite the exclusion of the Hirulog Angioplasty Study from bleeding outcome analysis, these results were also previously shown to correlate positively with maximum ACT but not initial ACT.

In addition, the specific device used to measure ACT is known to impact ACT values. For 85% of the patients, the device used to determine the ACT was recorded. When patients with ACT values recorded from the Hemochron device (95%) were analyzed separately, the range of optimal ACT remained unchanged, whereas the magnitude of difference between an ACT of 275 to 300 s and of 350 to 375 s increased marginally. As expected, an analysis of the 279 patients with ACT values recorded on the HemoTeck assay suggested optimal efficacy in the range of 300 to 325 s, which is consistent with the previously defined 28% lower readings with this device.

Finally, among the trials, the relationship between the ACT and ischemic events at 7 days demonstrates some heterogeneity, likely reflecting minor differences in patient populations and procedure-specific factors. Although these issues may contribute some degree of uncertainty in the absolute magnitude of benefit attainable with optimal heparin dosing, overall trends in benefit are similar among the trials. Operator-specific variations in procedural outcomes are inherent limitations of all large-scale studies involving technical procedures, both within and among trials. This limitation is somewhat mitigated by the randomized nature of each study and the availability of patient-specific data for incorporation into this analysis.

**Conclusions**

With the escalation in the cost of medical therapies, the optimization of current approaches remains as important as innovation. This meta-analysis of patient-specific data identifies an optimal level of ACT for patients undergoing PCI in the range of 350 to 375 s, a level of anticoagulation that runs...
contrary to recent clinical impressions. Furthermore, in sub-
groups at greater risk of thrombotic events, a steeper gradient
of benefit between lower and higher levels of ACT is evident.
However, this analysis also highlights the narrow therapeutic
range of unfractionated heparin therapy in PCI, demonstrat-
ing the increased bleeding risk incurred when targeting
maximal efficacy. Combined with the observed nonlinear
relationship between the ACT level and ischemic risk, these
data not only define an optimal range for individual patient
therapy, but they underscore the limitations of unfractionated
heparin. This analysis, therefore, delineates the benchmark of
both risk and benefit with unfractionated heparin therapy and
sets a standard for the development of new anticoagulant
strategies.

References
1. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation
of coronary-artery stenosis: percutaneous transluminal coronary angio-
2. Ragosta M, Karve M, Brezynski D, et al. Effectiveness of heparin in
preventing thrombin generation and thrombin activity in patients
clotting time during angioplasty and abrupt closure. Circulation. 1996;
93:667–671.
to dissection and thrombus formation during coronary angioplasty:
anticoagulation level and complications after successful percutaneous
coronary angioplasty-how much heparin is really warranted? Am J
9. The EPIC Investigators. Use of a monoclonal antibody directed against
the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angio-
10. EPIC Investigators. Platelet glycoprotein IIb/IIIa receptor blockade
and low-dose heparin during percutaneous coronary revascularization.
11. IMPACT-II Investigators. Randomised placebo-controlled trial of effect
of eptifibatide on complications of percutaneous coronary intervention:
IMPACT-II: Integrilin to Minimise Platelet Aggregation and Coronary
as compared with heparin during coronary angioplasty for unstable or
postinfarction angina: Hirulog Angioplasty Study Investigators. N Engl
benefits of coronary-artery stenting and blockade of platelet glycoprotein
IIb/IIIa receptors: Evaluation of Platelet IIb/IIIa Inhibition in Stenting
trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty
for acute myocardial infarction: ReoPro and Primary PTCA Organization
and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:
734–741.
high dose vs a weight-adjusted low dose of intravenous heparin during
17. Bittl JA, Ahmed WH. Relation between abrupt vessel closure and the
anticoagulant response to heparin or bivalirudin during coronary angio-
time and outcome after thrombolytic therapy for acute myocardial
infarction: results from the GUSTO-I trial. Circulation. 1996;93:
870–888.
19. Xiao Z, Theroux P. Platelet activation with unfractionated heparin at
therapeutic concentrations and comparisons with a low-molecular-weight
heparin and with a direct thrombin inhibitor. Circulation. 1998;97:
251–256.
concentrations augment platelet reactivity: implications for the pharma-
cologic assessment of the glycoprotein IIb/IIIa antagonist abciximab. Am
following coronary stenting. Heparin as a possible aetiological factor in
22. Moliterno DJ, Califf RM, Aguirre FV, et al. Effect of platelet glycop-
protein IIb/IIIa integrin blockade on activated clotting time during percu-
taneous transluminal coronary angioplasty or directional atherectomy (the
EPIC trial): Evaluation of c7E3 Fab in the Prevention of Ischemic Com-
23. Kleiman NS, Lincoff AM, Kereiakes DJ, et al. Diabetes mellitus, glyco-
protein IIb/IIIa blockade, and heparin: evidence for a complex interaction
in a multicenter trial: EPICLOG Investigators. Circulation. 1998;97:
1912–1920.
24. Avendano A, Ferguson JJ. Comparison of HemoChrom and HemoTec
activated coagulation time target values during percutaneous transluminal
Defining the Optimal Activated Clotting Time During Percutaneous Coronary Intervention: Aggregate Results From 6 Randomized, Controlled Trials
Derek P. Chew, Deepak L. Bhatt, A. Michael Lincoff, David J. Moliterno, Sorin J. Brener, Katherine E. Wolski and Eric J. Topol

_Circulation_. 2001;103:961-966
doi: 10.1161/01.CIR.103.7.961

_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2001 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/103/7/961

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org/subscriptions/